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Abstract	  	  Transfusion	  combined	  with	  iron	  chelation	  has	  been	  the	  paradigm	  for	  management	  of	  severe	  β-­‐thalassemia	   syndromes	   for	   over	   6	   decades;	   during	   which	   time	   both	   mortality	   from	  cardiosiderosis	   and	   quality	   of	   life	   have	   steadily	   improved.	   Transfusion	   aims	   at	   ameliorating	  anemia	  and	  suppressing	  erythron	  expansion	  while	  not	  transfusing	  more	  iron	  than	  is	  necessary.	  Blood	   transfusion	   inevitably	   leads	   to	   iron	   overload	   with	   secondary	   mal-­‐distribution	   of	   body	  iron.	  Overly	   intense	  transfusion	  regimens,	  as	  marked	  by	   low	  soluble	  transferrin	  receptors,	  not	  only	  increase	  the	  rate	  of	  body	  iron	  accumulation	  but	  also	  suppress	  endogenous	  erythropoiesis.	  	  Increased	   transfusion	   also	   decreases	   the	   ratio	   of	   chelation	   derived	   from	   red	   cell	   metabolism	  relative	  to	  chelation	  from	  hepatic	  stores.	  Conversely	  low	  transfusion	  rates	  increase	  endogenous	  erythropoiesis	   with	   the	   generation	   of	   iron-­‐free	   transferrin	   that	   can	   then	   bind	   NTBI	   species	  otherwise	  destined	   for	  myocardium	  or	   endocrine	   tissues.	   	  When	   the	   transfusion	   rate	   exceeds	  the	  clearance	  of	  transferrin	  iron	  by	  the	  erythron,	  the	  risk	  of	  cardiosiderosis	  is	  increased	  with	  an	  odds	  ratio	  of	  48.	  	  Cardiosiderotic	  risk	  is	  also	  increased	  when	  total	  body	  iron,	  as	  determined	  by	  LIC	  was	  not	  controlled.	  	  Optimal	  chelation	  dosing	  and	  regimen	  should	  aim	  to	  control	  body	  iron	  by	  balancing	   the	   transfusional	   iron-­‐loading	  rate	  with	   the	  chelation-­‐induced	  excretion	  and	  also	  providing	   24-­‐hour	   protection	   from	   plasma	   NTBI.	   Once	   cardiosiderosis	   has	   developed,	   its	  clearance	   even	   with	   intensified	   chelation	   often	   lags	   behind	   hepatic	   clearance.	   A	   systematic	  reappraisal	  of	  the	  impact	  of	  transfusion	  practices,	  particularly	  pre-­‐transfusion	  Hb	  values,	  on	  the	  success	  in	  preventing	  cardiosiderosis	  and	  chelation	  response	  is	  indicated.	  	  	  	  	  	  	  	   	  
1.	  Introduction	  
 
The benefits of both transfusion and chelation when used together are well established for transfusion-
dependent thalassemias. With the advent of newer chelation regimens and monitoring techniques, and 
in the light of recent data linking low erythron activity to increased risk of cardiosiderosis, a 
reappraisal of the optimal balance between transfusion rates and chelation may be warranted.  In this 
paper, current transfusion and chelation practices are critically reviewed with particular emphasis on 
how transfusion strategy affects iron distribution and the mechanisms through which this interaction 
occurs. The implications of this interaction for chelation strategy are also examined.  	  
2. Objectives of transfusion in thalassemias 
Blood transfusion in thalassemia aims to correct anemia so that physical and cognitive performances 
are close to healthy individuals, while preventing harmful or potentially disfiguring expansion of the 
erythron and not transfusing more blood and hence iron than necessary. Evidence for optimal 
hemoglobin (Hb) to achieve these goals was initially contradictory: some studies showed transfusion 
requirements remained constant at mean transfusion Hb levels of 10-14g/dL (equivalent to pre-
transfusion Hb 8-12g/dL)1,2, while others showed that transfusion requirements were directly 
proportional to the mean Hb3,4. In a later study, transfusion requirement was measured in the same 
patients under two transfusion regimens5: those with mean pre-transfusion Hb of 11.3g/dL had mean 
annual transfusion of 137mL/kg  but when the mean was subsequently lowered to Hb 9.4g/dl, annual 
consumption decreased to 104mL/kg/L and ferritin values fell.   
 
Current guidelines recommend pre-transfusion Hb values of 9.5-10.5g/dl, thus keeping the mean Hb at 
about 12g/dl with a post-transfusion Hb not above 14g/dl6. This 'sweet spot' for balancing 
considerations of iron loading and correction of anemia and ineffective erythropoiesis (IE) is based on 
a study of Italian patients5 and may not be applicable to patients with different levels of effective 
erythropoiesis (see below). Under certain circumstances, higher Hb levels may be appropriate, for 
example, when some patients experience low back pain at Hb < 10-11g/dl, or when the spleen size is 
expanding, or during pregnancy. The recommended frequency of transfusion every 2-4 weeks has 
been determined to some extent by the convenience to patients and the availability of blood in some 
regions. Mathematical modeling suggested pre-transfusion hemoglobin of 9g/dL with transfusions 
every two weeks rather than every four weeks would reduce requirements by 20% but no measurable 
effect was seen in a study comparing 3- or 4-week intervals4.  
 
Some populations are managed on lower pre-transfusion Hb values: for example, in 464 
Egyptian ΤDT patients aged 10 months to 31 years7,  the mean pre-transfusion Hb was 5.7g/dl.  In 
another study, the Hb values were significantly lower in patients from Cairo, Egypt (6.9g/dl) than 
from Ismir, Turkey (Hb 8.9g/dl, Y. Aydinok, personal communication). We suggest below that this 
variation in practice may account for differences in the proportion of patients with cardiosiderosis (see 
below). 
 
A further consideration is whether and when to start transfusion, particularly for milder syndromes. 
Many patients with milder phenotypes may not require transfusion in the first few years of life but as 
Hb values fall, particularly if there is failure to thrive, transfusion may become necessary.  Guidelines 
generally suggest Hb values repeatedly <7g/dl are suitable to begin transfusion but this approach may 
not be universally applicable, particularly in Eβ-thalassemia syndromes, where the oxygen 
dissociation curve is right-shifted relative to β-thalassemia syndromes. For example in a study where 
109 Eβ−thalassemia patients from Sri Lanka were followed for 5 years, the un-transfused group had 
Hb levels of 6.1g/dl and, based on performance status, did not require starting transfusion, while in a 
second group with mean Hb values of 7.0g/dl, 40% were able to stop transfusion without deleterious 
effects, despite the low Hb values8. These findings suggest that Eβ-thalassemia can be often managed 
without transfusion, even with low hemoglobin levels.  
 
3.  Body iron content and impact of transfusion.  
 
Thalassemia patients who are anemic but not receiving regular blood transfusion, so called non-
transfusion-dependent thalassemia (NTDT), absorb increased quantities of dietary iron, due to 
inappropriately low hepcidin relative to iron stores, that may not be balanced by insensible iron losses, 
so that iron overload gradually develops9. Excess iron absorption depends on the degree of IE, the 
extent of erythroid expansion and the severity of anemia. Iron absorption rates determined with radio-
isotope markers, showing absorption of 5 times that of healthy controls were reported in β-thalassemia 
intermedia  (range 3-10 times)10. This was similar in Eβ-thalassemia, where studies also showed that 
iron absorption correlated with plasma iron turnover, transferrin saturation, and liver iron 
concentration11. Iron absorption over 1 year has now been determined in larger populations, using 
MRI to measure changes in LIC12 and hence calculate net iron absorption13. LIC and serum ferritin 
increased from baseline by 0.38mgFe/g dry weight and 115ng/mL, respectively. This increase in LIC, 
is equivalent to an average iron accumulation rate of 0.011mg/kg/day12. Increased iron absorption is 
currently thought to result from inhibition of hepatic hepcidin synthesis by bone-marrow-derived 
factors associated with IE and leading to inappropriately low hepcidin levels relative to iron stores9. 
Implicated factors have included growth differentiation factor-15 (GDF-15) in humans14 and, more 
recently, erythroferrone in mice15. GDF-11 has also been identified as a factor associated with IE in a 
murine thalassemia model16. Iron overload in NTDT correlates with erythron expansion biomarkers 
(sTfR, GDF-15, NRBCs), particularly in un-transfused, such as Hemoglobin H, patients9. Plasma 
hepcidin correlates inversely with TfSat, NTBI and LPI9, consistent with a link between iron 
absorption and depressed hepcidin levels. Hepcidin/SF ratios were also low, consistent with hepcidin 
suppression relative to iron overload9. Increased NTBI and, by implication, risk of extra-hepatic iron 
distribution was more likely in previously transfused, splenectomized and iron-overloaded NTDT 
patients with TfSat>70%9.  
 
The iron-loading rate from blood transfusion in TDT is about 10 times the rate seen in NTDT or 20-
35mg/day in a 70kg adult17. This is because of the high iron content in a unit of blood: a unit of red 
cells, processed from 420mL of donor blood, contains approximately 200mg of iron (or 0.47mg/mL of 
whole donor blood equivalent to 1.16mg/mL of pure red cells). The mean loading rate is 
approximately 0.4mg/kg/day17 equivalent to 28mg/day of iron in 70 kg adult. About 20% of patients 
receive <0.3mg/kg/day, about 60% receive 0.3-0.5mg/kg/day, and a further 20% >0.5mg/kg/day of 
iron. Without chelation therapy, LIC reaches 15mg/dry weight after less than 5 years of blood 
transfusion. Average transfusion requirements are somewhat higher in un-splenectomized 
(0.43mg/kg/day) TDT patients compared with splenectomized patients (0.33mg/kg/day)17. Thus 
splenectomized patient receive the equivalent of 300 mL less of whole blood per kg per annum 
decreasing the annual iron loading by 39%. This is not sufficient reason to recommend splenectomy 
due the high complication rates and because modern chelation regimes can generally keep pace with 
this difference in iron accumulation. In patients who develop splenic enlargement, hypertransfusion 
can often diminish spleen size without the need for splenectomy18.  
 
4.  Mechanisms of body iron distribution in thalassaemias  
 
In the absence of blood transfusion, excess absorbed iron is found in the peri-portal hepatocytes in 
NTDT19 and extra-hepatic iron distribution is very rare20,21. However with blood transfusion in TDT, 
iron accumulates initially in the macrophage system after erythrophagocytosis of transfused red cells. 
Red cell heme is catabolized here by haemoxygenase with iron rapidly released through ferroportin 
channels for extracellular binding to transferrin. Alternatively, when hepcidin binding to membrane 
ferroportin degrades this molecule, more iron can be retained within macrophages as storage iron 
(ferritin or hemosiderin).  The macrophage system is considered capable of storing about 10g of iron 
(or about 50 units of transfused blood).  
 
Once the macrophage system is replete, increasing proportions of storage iron are delivered to 
hepatocytes though diferric transferrin and/or through plasma iron species occurring when transferrin 
saturation exceeds about 75%, the so-called plasma non-transferrin-bound iron, NTBI. Unlike 
transferrin-bound iron, which is targeted through transferrin receptors to the erythron or to 
hepatocytes, NTBI species are taken into endocrine system and myocardium, in addition to 
hepatocytes, probably though LVDCC channels into myocardium22 and possibly, also though Zip14 in 
the endocrine system23.  The cells known to take up NTBI are similar to those tissues susceptible to 
the effects of transfusional iron overload (see below). Clinical conditions associated with high plasma 
NTBI, such as TDT and DBA, are associated with high NTBI levels. Conversely, conditions with low 
NTBI levels even where severe iron overload co-exists, such of NTDT and sickle cell disease, have a 
low propensity to extra-hepatic iron distribution24. Levels of NTBI are affected by several independent 
factors24, being raised by iron overload, but are also raised when erythropoiesis is relatively inactive, 
such as in myelo-ablative chemotherapy, due to decreased clearance of transferrin-iron by the 
erythron25 or when erythropoiesis is constitutively inactive, such as in DBA24 (Figure 1). 
 
Cellular iron uptake from NTBI is not only dependent on plasma levels but also on its speciation26. 
NTBI is heterogeneous consisting largely of iron-citrate species where the molecular weight of the 
iron-citrate complex is determined by the ratio of constant plasma citrate concentrations to the 
variable concentrations of NTBI27.  Recent work suggests that the makeup of iron citrate species (their 
speciation) has a key impact on the iron uptake into tissues such as myocardium26.  Thus  iron uptake 
in HL-1 cardiomyocytes and generation of intracellular ROS occured most rapidly when citrate 
exceeded iron(III) by more than 100:1. Such conditions favor kinetically labile monomer (monoferric) 
rather than oligomer citrate species. These same species are those detected by the LPI assay which 
measures the redox-active compnent of NTBI28.  Monoferric species also bind most rapidly to apo-
transferrin, which therefore readily inhibits cellular iron uptake of these NTBI species26. Thus apo-
transferrin generated by high transferrin-iron utilization in an active bone marrow can inhibit NTBI 
tissue uptake by rapidly binding monoferric-citrate species (see below). Therefore the activity of the 
erythron is critical to NTBI speciation and hence body iron distribution. This expains why patients 
with iron overload but with little utilization of transferrin-iron, such as DBA or heavily hyper-
transfused TDT patients, may be particularly susceptible to extra-hepatic iron distribution.  
 
The clinical consequences of this iron distribution, including cardiomyopathy, endocrinopathy, and 
bacterial infections, have been recently described and reviewed by the senior author29. The generation 
of ROS by iron that redox-cycles between iron(II) and iron(III) is the major driver of oxidative tissue 
damage and iron chelation therapy has had a major impact on the frequency of these complications30.  
 
5.  Effect of blood transfusion regimen on iron distribution 	  
a) Effect of cumulative blood transfusion on iron distribution  
 
In the absence of regular transfusion in NTDT, a lack of cardiosiderosis has been consistently 
reported20,21. However, once transfusion begins in TDT, there is a clear link between the risk of 
myocardial iron accumulation and the cumulative volume of blood transfused. This was clear in the 
pre-chelation era31 where interpretation was not muddied by chelation altering the relationship 
between liver and cardiac iron. Post mortem data on multi-transfused patients with a variety anemias 
showed that 100% of patients had evidence of increased cardiosiderosis after 200 transfused units31.  
The proportion fell as the number of transfused units decreased; thus 60% of patients had increased 
heart iron after 100 units, but only 10% after 25-50 units31. Early MRI studies also reported that 
myocardial iron increased in myelodysplastic patients with the number of transfused blood units and 
with LIC32. In studies failing to show such a link33, interpretation has been confounded by recent 
chelation therapy, which perturbs the apparent relationship between liver and heart iron due to more 
rapid removal of liver than heart iron. It is important to examine trends of heart and liver iron over 
time, where a clear relationship between these has been shown in chelated patients with heart changes 
following those in the liver34.  	  
b) Effect of intensity of transfusion regimen on iron accumulation and iron distribution 
 
The intensity of blood transfusion can be represented by the pre-transfusion Hb combined with the 
frequency of transfusion, which contribute to mean Hb.  The higher this is, the greater the suppression 
of endogenous erythropoiesis5. The most robustly studied marker of extra-hepatic iron is myocardial 
T2*33. Little direct prospective information about its relationship to variables in blood transfusion 
regimens exists, however several lines of evidence suggest a relationship.  The first comes from the 
lack of cardiosiderosis in heavily iron overloaded NTDT patients20,21. The next comes from surprising 
disparity in the frequency of cardiosiderosis between Middle-Eastern and European countries.  
Baseline data from 11 countries of 925 patients, mainly with TDT (>99%)35 found the frequency of 
cardiosiderosis (T2*<20ms) was notably lower in the Middle East (28.5%) than Europe (49.5%) or 
Asia-Pacific (40.9%)35.  This was despite the proportion of patients with LIC values >15mg/g dry 
weight being higher in the Middle East (63%) than Europe (51%). Similar observations have been 
reported in Egyptian patients36. The reason is not immediately obvious: genotypic regional differences 
in thalassemia mutations are unlikely to explain these findings as systematic differences in frequency 
of abnormal myocardial T2* have not been noted in migrants from these countries to Europe.  In 
Oman, incidences of abnormal T2* are high (46%) compared to elsewhere in the Middle-East which 
is more likely to be due to difference in clinical management than to genetic differences from 
elsewhere in the Middle-East Region as the genotypes are highly heterogeneous37.  
 
Could differences in chelation policy account for the low prevalence of abnormal myocardial T2* in 
the Middle East ? Again, this is unlikely, Middle-Eastern patients were generally poorly chelated, with 
high LIC and ferritin, and indeed many patients had received little or no chelation, and had spent  
highest proportions of their lives without any chelation than other regional groups35. Unfortunately, 
the pre-transfusion Hb values were not given. However, the proportion of patients going more than 
four weeks between transfusions was highest in the Middle-Eastern patients (13%) compared with 
Europe (2.3%) or Asia-Pacific (5.5%), transfusion episodes being lowest in the Middle East. In 
Europe, transfusion regimens close to TIF guidelines are generally followed, with pre-transfusion Hb 
values of 9.5-10.5g/dl which would cause a significant suppression of endogenous erythropoiesis 
using the model of Cazzola5. By contrast, reports from Egypt, for example, show pre-transfusion Hb 
values of 7.5g/dl or less. In another study, with over 1700 patients, an analysis of transfusion and 
chelation policy by region (EPIC study)38 showed lower annual volume of blood transfused in the 
Middle East than in Europe or Asia-Pacific.   
 
c) Differences in the activity of erythron with transfusion as marked by soluble transferrin receptors 
 
The possibility that transfusion policy may impact on cardiosiderosis is strengthened by a recent study 
where the suppression of the erythron, as marked by sTfR, when combined with a high transfusion-
iron loading rate was the greatest predictor of cardiosiderosis26 (Figure 2). In this study, a large 
number of risk factors for cardiosiderosis were examined in 73 patients. sTfR levels were significantly 
lower in patients with cardiosiderosis (odds ratio 21) and this risk increased further when the 
transfusion-iron loading was taken into account. When rates exceeded the erythroid transferrin uptake 
rate (derived from sTfR1)26 by >0.21 mg/kg/day, the odds ratio increased to 48. High levels of LIC, 
ferritin and LPI were also risk factors but less strongly. High levels of bilirubin, reticulocyte counts or 
low hepcidin were associated with lower risk. A unifying mechanism for these risks, as discussed 
above, is that unsaturated transferrin is generated by an active bone marrow which in turn removes 
forms of NTBI such as LPI that would otherwise be taken into myocardium. This suggests transfusion 
policy and, in particular, the average Hb levels, estimated by pre-transfusion Hb, will have a key 
impact on the cardiosiderotic risk. We suggest that regional differences in risk may relate to 
differences in transfusion policy.  
 
Interestingly, the sTfR-estimated erythropoietic expansion was also more predicated by the age of 
onset of transfusion dependence than by subsequent years of transfusion26. Other data, comparing 
1266 TDT patients across 70 centers, support this, where sTfR levels relate to EMH39 and that where 
EMH persists despite transfusion, patients do not develop cardiosiderosis40.  Furthermore, in 
transfused sickle cell disease, the reduction of reticulocytes to <5% predicts future development of 
cardiosiderosis41. This points to a fundamental role for residual erythropoiesis in extra-hepatic 
hemosiderosis. If residual erythropoiesis is maintained at a reasonable level (sweet spot), this 
constitutes a safety valve against toxic NTBI species and cardiosiderosis26 
 
d) Control of iron retention in tissues through ferroportin-hepcidin interactions 
 
Recent animal work provides novel insight into consequences of ferroportin/hepcidin interaction for 
the extra-hepatic complications of TDT42–44. This work highlights the importance of cellular iron 
egress, rather than just uptake, to cardiomyocyte iron retention. The hemochromatotic model, resulting 
from a ferroportin mutation conferring resistance to hepcidin with unhindered ferroportin patency, 
causes fatal exocrine pancreatic failure due to iron overload of the acinar cells42. These never express 
ferroportin and so, unlike myocardium and endocrine system, are unable to export iron acquired from 
NTBI42. Hence cardiac-specific knock-out of ferroportin, as confirmed elsewhere, results in 
cardiosiderosis43,44. Thus we predict that this under-recognized balance of NTBI uptake to ferroportin-
mediated release is potentially important to net cardiosiderosis clinically.  
 
Another mechanism by which a low transfusion regimen in TDT may result in decreased 
cardiosiderosis is therefore through decrease of hepcidin. We have shown that high plasma hepcidin is 
related to cardiosiderosis in TDT, although not as strongly as is low sTfR (low ETUR)26. We can 
speculate that a low transfusion regime results in lower hepcidin because of less marrow suppression. 
Increased hepcidin, either post-transfusion45,46, or as part of high transfusion regimes, is compounded 
by the switching off of the erythroid iron uptake (safety valve for LPI26) thus subjecting 
cardiomyocytes to a double impact of high LPI/NTBI exposure and limited cardiac iron exit via 
hepcidin-controlled ferroportin.  
 
6.  Interaction of blood transfusion and chelatable iron pools  
 
The structure, mechanisms of iron binding, pharmacokinetics, and clinical effects of the clinically 
licensed iron chelators, desferrioxamine (DFO), deferiprone (DFP) and deferasirox (DFX), have been 
described in detail recently by the senior author30,47, and will not be repeated here in detail.  This 
section will focus of the interaction of blood transfusion on iron chelation therapy.  
 
a) Interaction of transfusion with chelatable iron pools 
 
Early studies on DFO showed a relationship between blood transfusion and chelatable iron48. When 
DFO binds iron to form ferrioxamine (FO) the iron is derived from two key pools: firstly, the liver 
and, secondly, from erythrocyte catabolism by macrophages in spleen, liver and bone marrow. DFO is 
highly efficient at chelating liver iron because of rapid uptake into the hepatocytes49. FO can be 
eliminated in urine or in bile (feces) but is derived from two different sources. Urinary FO is derived 
from erythrocyte catabolism whereas fecal FO is mainly derived from hepatic iron. The proportion of 
endogenous red cells is higher pre- than post-transfusion. This leads to increased peripheral hemolysis 
as well as more intramedullary IE, which in turn increases the magnitude of the chelatable iron pool 
from red cell catabolism. This iron pool is excreted in urine. Thus pre-transfusion, at low Hb values, 
urinary iron excretion of FO, derived from erythrocyte catabolism, increases whereas fecal iron 
excretion is relatively unaffected or decreases slightly.  
 
Factors affecting chelatable iron pools with DFP are less fully described than with DFO and even less 
is known about the effect of the transfusional iron-loading rate. However we have examined iron 
pools that are chelatable with DFP by measuring concentrations of the DFP iron complex in plasma at 
the same time as measuring 24-hour urine iron excretion50. Chelated iron in the plasma compartment 
(forms ferriprone, FP, which is detected using the NTBI assay 50, Figure 3C) was greatest in patients 
with the highest LIC levels, as might be expected, but also greater in those with lowest transfusional 
iron-loading rate (Figure 3A, 3B), where hemolysis and/or IE are greater.  Increments of plasma FP 
also correlate with total urine iron excretion (UIE) and with decrements in LIC over the next year 
(Figure 3D, 3E). Thus blood transfusion decreases the iron available for chelation by DFP in the 
plasma compartment by decreasing IE and hemolysis. Conversely, high blood transfusion rate 
increases total body iron, which in turn increases the LIC-derived pool available for chelation (Figure 
3A).  
 
b) Interaction of blood transfusion with chelator dose needed for iron balance 
 
Iron balance is simply the difference between iron input from gastrointestinal plus transfusional and  
iron output from chelation. From first principles, the dose of chelation needed under conditions of low 
transfusion would be better than at high transfusion rates. Body iron can be calculated from LIC using 
the Angelucci formula13 and hence change in LIC can be used to calculate changes in body iron over 
time.   
 
The interaction of transfusion rate with total iron excretion has been described using this approach for 
both DFO and DFX. With DFO, at typical transfusional iron loading rates (0.3–0.5mg/kg/d), negative 
balance was achieved in 75% of patients prescribed subcutaneously 35-49mg/kg/d 5 days/week, 
whereas at doses of 50mg/kg/d or greater, response rates increased to 86%. At higher iron loading 
rates (>0.5mg/kg/d), response was seen in only half of the patients prescribed subcutaneously 35-
49mg/kg/d 5 days/week, but by increasing this dose to 50mg/kg or greater response increased to 
89%17.  With DFX, the importance of the blood transfusion rate to iron balance has also been shown 
using this approach. At low transfusion rates <0.3mg/kg/d, 96% of patients have a negative iron 
balance at 30mg/kg/d whereas at higher transfusion rates, only 82%17. The principle of adjusting dose 
to transfusional loading rate has been built into drug labeling and into the design of further studies of 
efficacy where serum ferritin was used to adjust dose even though this is a less precise marker of iron 
balance than LIC.  
 
With DFP, data on the effects of transfusion rate on chelation efficacy is not so clear from prospective 
trials but useful data are available from retrospective analysis of LIC trends using SQUID 
(Superconducting Quantum Interference Device biomagnetometry) in 54 β-thalassaemia major 
patients receiving DFP (75mg/kg/d) or 51 patients receiving DFO51. Detailed contour plots of the 
interaction of transfusion with chelation dose were undertaken for both drugs. At 30mg/kg/d of DFO 
(a low dose), negative iron balance was achieved when transfusion rates were less that 22mg/day for 
total body iron stores exceeding 4g or when transfusion rates were less than 17mg/day for total body 
iron stores exceeding 1g. With DFP at 75mg/kg/d, negative iron balance was achieved when 
transfusion rates were less than 17mg of iron/day for total body iron stores exceeding 1.8g. Higher 
doses of both chelators could achieve negative iron balance when the transfusion rate was more than 
described. In conclusion, the successful dose for balancing input and output of iron of each form of 
monotherapy is critically dependent of the blood transfusion rate in the treatment group. 
 
Other factors affecting extra-hepatic iron removal with chelation therapy 
 
The authors do not regard blood transfusion as the sole factor affecting iron removal from extra-
hepatic tissues; simply that this factor may have been overlooked to some extent. Other factors are 
clearly important.  For removing myocardial iron, which can be achieved with all chelators used alone 
or in combination30, removal of liver iron generally occurs at a much faster rate than from the heart, as 
shown elegantly by trajectory trends for myocardial and liver iron assessed by serial MRI34. Removing 
iron from the liver improves removal of myocardial iron: for example in a subsidiary EPIC study on 
DFX, improvement of cardiac T2* was progressively better from 12 to 36 months in patients who 
achieved LIC values <7mg/g dry weight than those with LIC values >15mg/g dry weight52. Baseline, 
or pre-treatment, LIC values also seem to impact on success of removing cardiosiderosis. Thus in the 
'Cordelia' DFX study, the % improvement in cardiac T2* with DFX at 1y was greater (17%) in 
patients with baseline LIC <7mg/g compared to those with baseline LIC >15mg/g dry weight (9% 
improvement)53 and this pattern was sustained at 2 years54. 
 
Regimes where there is 24-hour presence of a chelator in plasma are preferable, as they provide 
continuous protection from NTBI or LPI uptake since these rebound rapidly after stopping 
treatment55,56. However, not all forms of NTBI, available for uptake into cardiomyocytes, are equally 
inhibited26. The rate of access of the free chelator ligand and the rate of egress of the iron complex, 
determined by the size, charge, and lipid solubility57, are important to their ability to chelate 
intracellular iron pools. DFP, by virtue of its neutral charge and low molecular weight, has faster 
kinetic access to intracellular iron pools than DFO58.  The interpretation of clinical studies however is 
somewhat problematic because randomized head-to-head comparison of DFP with DFO have used 
suboptimal low doses of DFO but relatively high doses of DFP59,60 and baseline LIC values often vary 
considerably between studies. The issue of combination of chelators providing a shuttling mechanism 
to enhance chelation rates is theoretically justified61–63, but the extent to which shuttling contributes to 
enhanced chelation, if the drugs are not given simultaneously, is questionable. Clinical benefit from 
sequential combinations is more likely to be a consequence of greater overall exposure to chelation, 
contributed to by improved adherence.  
 	  
Figure legends 
Figure 1. Factors influencing the generation of NTBI. (adapted from Porter et al 2014, BJH) 
 
Figure 2. Statistically significant risk factors for cardiosiderosis in TDT. 
In 73 patients (24 with and 49 without cardiosiderosis) various relevant factors were assessed (after 
Garbowski et al 2017, Haematologica) for a relationship with cardiosiderosis. Thresholds protecting 
from cardiosiderosis are shown. ROC curves were constructed for every variable and a threshold 
protecting from cardiosiderosis for highest likelihood ratio was reported. Strength of association was 
expressed using an odds ratio. Factors not associated with cardiosiderosis were NRBC, total serum 
iron, weight, ILR, transferrin saturation, GDF-15, NTBI, years of transfusion dependence. LPI, labiile 
plasma iron; abs retic, absolute reticulocyte count; ETU erythroid transferrin uptake; sTfR, soluble 
transferrin receptor 1; ETUR, erythroid transferrin uptake rate; ILR, iron load rate 
 
Figure 3. The effect of transfusion and iron stores on chelatable iron pools. 
Relationship of the 1-week change in NTBI after commencing deferiprone therapy to baseline LIC (A) 
and the reciprocal of transfusion iron-loading rate, 1/TIRL (B). 1-week change in NTBI correlates with 
plasma ferriprone levels (C), with urinary iron excretion (D) and with change in LIC after 1 year (E). 
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